Marco Meglio

In part 2 of this interview, Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, describes how her resident program experience was impacted by the pandemic.

The percentage of patients reporting no OFF time and no impact of OFF on daily function more than doubled by the first on-treatment visit in this open-label trial.

Benefits of levodopa-carbidopa intestinal gel lasted throughout the day and showed greater benefits of continuous dopaminergic stimulation in disease control than immediate release oral capsules.

Improvement in dyskinesia occurred after 2 weeks of treatment with levodopa-carbidopa intestinal gel and was sustained throughout the study.

No new safety signals were observed in the combined analysis of ponesimod from the phase 2b core study and extension study.

Supporting patient activation of their knowledge, skill, and confidence in managing their health may empower patients in times of stress.

Scores reflective of tremor in each body part and task performance improved by 71% in patients from baseline before first thalamotomy to 6 months after second thalamotomy.

After 3 months of treatment, an overwhelming number of clinicians and patients preferred directional over omnidirectional DBS.

Treatment-naïve patients showed consistent results with the overall study population that was observed in the ASCLEPIOS I and II trials.

Patients with relapsing multiple sclerosis and high levels of fatigue were less likely to be employed full-time than those with MS with low fatigue.

Financial self-efficacy and having at least 1 relapse were identified as independent predictors of financial toxicity among patients with multiple sclerosis.

Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, shares details from her study on the psychosocial impact on physicians and her first-hand experience.

Researchers noted that the findings are encouraging for the use of real-world data and natural history data to augment, or possibly replace, placebo controls in DMD trials.

Treating patients with super-refractory status epilepticus with ketamine showed no effect on intracranial pressure, cerebral blood flow, and cerebral perfusion pressure.

Among individuals at high risk for recurrent ICH, the use of selective serotonin reuptake inhibitors was associated with a greater increase in repeated hemorrhagic stroke.

Despite previous literature documenting cardiovascular disease comorbidity in patients with narcolepsy, pitolisant treatment did not demonstrate any cardiac safety signals.

The researchers noted that future studies should examine the cost-effectiveness of CT compared with MRI as the best initial imaging modality for mechanical thrombectomy.

The FDA-approved epilepsy monotherapy showed significant reductions in primary generalized tonic-clonic seizures of ≥50% and ≥75% from baseline.

A low glycemic index therapy diet is associated with the least number of and least severe adverse events among all 3 epileptic diet methods, with similar reductions in seizure burden.

The FDA-approved agent showed significant impact in decreasing standard deviation of lateral position, a measure used to assess driving performance.

Already FDA approved for the treatment of insomnia in adults, lemborexant’s ability to improve sleep outcomes in the elderly was highlighted in a study presented at SLEEP 2020.

In part 2 of this interview, Marwan Sabbagh, MD, provides insight on what he feels is the most promising field of research in Alzheimer disease right now.

With a positive track record in ALS, the investigational agent now sets its sights on the Alzheimer disease pipeline.

Benefit from lemborexant was evident after 1 month of switching from placebo to the active treatment and was sustained through the entirety of the 12-month trial.

Increased consumption of vegetables, nuts, and moderate alcohol intake are each inversely associated with the odds of 3 or more prodromal features that precede Parkinson disease.

In part 2 of this interview, Hubert Fernandez, MD, director of the Center for Neurological Restoration at Cleveland Clinic, detailed the greatest unmet needs as well as the utility of deep brain stimulation in patients with Parkinson disease.

Recognition of the distinct neuroanatomical patterns, symptoms, and rates of progression within different biotypes can play a pivotal role in the implementation of precision medicine for Parkinson disease.

Researchers noted that further examinations are needed of the genetic heterogeneity depression syndromes to test for causal relationships between distinct subtypes of depression and Alzheimer disease.

Neurological deterioration was observed in about 1 of 7 patients who received in-hospital care for acute ischemic stroke or transient ischemic attack.

Marwan Sabbagh, MD, director of the Lou Ruvo Center for Brain Health and a neurologist at Cleveland Clinic, detailed why aducanumab’s upcoming FDA decision bears immense weight for patients with Alzheimer disease and future clinical studies.